Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance

International Journal of Antimicrobial Agents

Volumn 30, Issue 1, 2007, Pages 93-94

  Pasqualotto, Alessandro Comarú ^a   Denning, David W ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; ITRACONAZOLE;

ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MYCOSIS; PRIORITY JOURNAL;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE, FUNGAL; DRUGS, GENERIC; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 34249940274     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.11.027     Document Type: Letter

References (5)

1. Stevens D.A., Kan V.L., Judson M.A., et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30 (2000) 6696-6709
2. Prentice A.G., and Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 56 Suppl. 1 (2005) i17-i22
3. Law D., Moore C.B., and Denning D.W. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 38 (1994) 1561-1566
4. Denning D.W., Riniotis K., Dobrashian R., and Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature and review. Clin Infect Dis 37 Suppl. 3 (2003) S265-S280
5. European Agency for the Evaluation of Medicinal Products (EMEA). Guidance on the investigation of bioavailability and bioequivalence. Available at: http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf [accessed 23rd March 2007].